MET-097i (PF'3944): Pfizer's Monthly GLP-1 Shot Explained

Every approved GLP-1 medication for obesity asks the same thing of patients: an injection every seven days, indefinitely. MET-097i — now carried in Pfizer's pipeline as PF'3944 — is engineered to ask for one every 28 days instead. Its half-life is roughly 16 days, long enough that a single subcutaneous dose keeps drug levels in the therapeutic range for a month.

Pfizer paid up to $10 billion for that molecule. In November 2025, after a two-week bidding contest with Novo Nordisk, it acquired Metsera, the biotech that developed MET-097i, at $65.60 per share in cash plus contingent value rights worth up to $20.65 more. Two phase 2b readouts have since landed, and the drug is heading into ten phase 3 trials.

The question worth asking is not whether monthly dosing sounds convenient. It is whether MET-097i gives up efficacy to get there — and what the tolerability data suggest about who might tolerate it when weekly drugs have failed them.

What MET-097i Actually Is

MET-097i is a lipid-conjugated peptide GLP-1 receptor agonist. Two design decisions separate it from semaglutide and tirzepatide.

First: albumin hitchhiking taken to an extreme. The molecule was built on Metsera's HALO lipidation platform, which attaches a lipid tail engineered so the peptide binds human serum albumin and the GLP-1 receptor at the same time. Semaglutide uses a related trick — a C18 fatty diacid chain that binds albumin and stretches its half-life to about seven days. MET-097i pushes the same principle much further. Phase 1 pharmacokinetics showed a half-life near 380 hours, roughly 16 days, with dose-linear behavior and consistency from subject to subject. That is two to three times the durability of existing peptide GLP-1s.

Second: signaling bias. MET-097i is described by its developers as a "fully biased" agonist — it drives cAMP signaling at the GLP-1 receptor while largely avoiding β-arrestin recruitment. β-arrestin is the protein that pulls an activated receptor inside the cell and shuts it down. Agonists that recruit it heavily cause receptor internalization and desensitization; agonists that skip it keep receptors on the cell surface and signaling longer.

Preclinical work supports the rationale. In a 2025 Cell Reports Medicine study, a cAMP-biased compound with almost no β-arrestin recruitment kept GLP-1 receptors at the cell surface and outperformed liraglutide on weight loss in diet-induced obese mice.

Evidence: The biased agonist showed "negligible (<5%) recruitment" of β-arrestin at GLP-1R and GIPR. — Rodriguez R, et al. Cell Rep Med. 2025. 10.1016/j.xcrm.2025.102156

That evidence is preclinical and involves a different molecule. It explains why the design is plausible, not that MET-097i's human tolerability comes from bias specifically.

Why Monthly Dosing Solves a Real Problem

Convenience framing undersells the case. The strongest argument for a monthly GLP-1 is that most people stop taking the weekly ones.

A cohort study of 125,474 US adults initiating GLP-1 receptor agonists found that among patients without type 2 diabetes — the population using these drugs for weight management — 64.8% had discontinued within one year, and 84.4% within two years.

Evidence: "Adverse effects and cost were the most frequent specific reasons for discontinuation." — Rodriguez PJ, et al. JAMA Netw Open. 2025. 10.1001/jamanetworkopen.2024.57349

Since weight regain after stopping a GLP-1 is the rule rather than the exception, a drug that people actually stay on is worth as much as a drug that produces a larger number in a trial.

Injection frequency itself carries measurable cost to patients. A general-population preference study across the UK, Canada, and China quantified the quality-of-life penalty of moving from weekly to daily GLP-1 injections in obesity at −0.0404 (UK), −0.0329 (Canada), and −0.0950 (China) utility units. No equivalent study has yet measured monthly versus weekly, so extending that logic forward is inference, not evidence.

Two practical benefits are less speculative. Twelve injections a year instead of 52 cuts injection-site reactions and needle-related anxiety proportionally. And a monthly dose is far harder to forget than a weekly one that competes with travel, illness, and pharmacy gaps.

VESPER-1: The Weekly Efficacy Data

VESPER-1 was a randomized, double-blind, placebo-controlled phase 2b trial in 239 adults with overweight or obesity and no type 2 diabetes. Mean BMI was about 36; roughly two-thirds of participants were female. Four weekly dose arms ran for 28 weeks — with no titration, which matters, because titration is how every marketed GLP-1 manages early nausea.

Weekly dose	n	Placebo-adjusted weight loss (wk 28)
0.4 mg	54	8.1%
0.6 mg	54	10.0%
0.9 mg	53	13.0%
1.2 mg	54	14.1%

Individual responses in the top dose arm reached 26.5%. Weight loss was still declining at week 36 in the extension, meaning the curve had not flattened when the data were cut.

The dropout figure is the one that drew attention: 2.9% total study discontinuation, with only two of 239 participants stopping treatment because of adverse events. For context, phase 3 obesity trials of marketed GLP-1s typically report treatment discontinuation from adverse events in the mid-single digits, and real-world numbers are far worse.

Gastrointestinal side effects did occur. At the 1.2 mg untitrated dose, risk differences versus placebo ran 4–23% for nausea, 4–15% for vomiting, and 0–13% for diarrhea across cohorts.

VESPER-3: The Monthly Efficacy Data

VESPER-3 is the trial that tests the actual product concept. Announced by Pfizer on February 3, 2026, it enrolled roughly 54 participants per arm across five arms, titrating weekly through week 12 and then switching to monthly maintenance dosing from weeks 12 to 28. Total study duration is 64 weeks; these are the 28-week topline results.

Regimen (titration → maintenance)	Placebo-adjusted loss, wk 28
0.4 → 0.8 mg QW, then 3.2 mg monthly	10.0%
0.8 mg QW, then 3.2 mg monthly	not disclosed
0.4 → 0.8 → 1.2 mg QW, then 4.8 mg monthly	12.3%
0.6 → 1.2 mg QW, then 4.8 mg monthly	not disclosed

All four regimens beat placebo (P < 0.001). The two bolded regimens are the ones Pfizer is carrying into phase 3.

Two caveats belong next to those numbers. First, under a treatment-policy estimand — which counts participants who stopped drug or added other weight-loss treatment — the same arms produced 8.4% and 10.5%, not 10.0% and 12.3%. Both estimands are legitimate; the higher figures answer "what does the drug do when taken," the lower ones "what happens to everyone randomized." Second, only two of five arms had efficacy disclosed in the topline release.

The mechanistically important finding is what happened at the weekly-to-monthly switch: weight loss continued rather than stalling, with no plateau by week 28. If monthly dosing produced meaningful trough exposure gaps, weight regain between doses would be the expected signal. It was not observed.

Safety was consistent with VESPER-1. Gastrointestinal events were predominantly mild or moderate, with no more than one instance of severe nausea or vomiting in any dose group and no severe diarrhea. Across the two lead arms, five participants discontinued for adverse events during the weekly phase and five during the monthly phase; placebo had zero.

How MET-097i Compares

Cross-trial comparison is the weakest form of evidence in this field, and the timepoint mismatch here is severe — 28 weeks against 52 to 72 weeks. Weight-loss curves are still steep at 28 weeks. Read this table as orientation, not ranking.

Drug	Dosing	Trial	Duration	Mean weight change
MET-097i	Monthly (after titration)	VESPER-3	28 wks	−12.3% placebo-adj.
MET-097i	Weekly, no titration	VESPER-1	28 wks	−14.1% placebo-adj.
Semaglutide 2.4 mg	Weekly	STEP 1	68 wks	−14.9% (placebo −2.4%)
Tirzepatide 15 mg	Weekly	SURMOUNT-1	72 wks	−20.9% (placebo −3.1%)
Maridebart cafraglutide	Monthly	Phase 2	52 wks	up to −20% (placebo −2.6%)

Evidence: Once-weekly semaglutide produced a mean body-weight change of −14.9% at week 68. — Wilding JPH, et al. NEJM. 2021. 10.1056/NEJMoa2032183

The honest read: MET-097i is not positioned to beat tirzepatide on raw efficacy. Its case rests on a different axis — comparable-tier weight loss delivered monthly, with dropout rates that look better than the class.

Its closest competitor is MariTide, Amgen's once-monthly peptide–antibody conjugate, which reported up to 20% weight loss at 52 weeks but with a heavier early gastrointestinal burden. MariTide is further along; MET-097i appears better tolerated. Those two facts will define the monthly-dosing market.

What Remains Unknown

No peer-reviewed publication. Every MET-097i efficacy figure here comes from company announcements and topline press releases. Detailed VESPER-3 data were presented at the American Diabetes Association's 86th Scientific Sessions on June 6, 2026, but full peer-reviewed publication has not appeared. Press-release numbers are selected by the sponsor.

Body composition. No lean-mass data have been released. Given that monthly dosing produces a different exposure profile than weekly, whether the fat-to-lean loss ratio differs is an open and clinically relevant question.

Long-term durability. Twenty-eight weeks is short. The 64-week VESPER-3 data will show whether monthly maintenance holds through the plateau phase where weekly drugs typically stall.

Cardiovascular and metabolic outcomes. No outcomes trial has read out. Semaglutide and tirzepatide now carry outcome data that MET-097i will need years to match.

The amylin combination. MET-233i, a monthly amylin agonist from the same platform, produced 8.4% placebo-subtracted weight loss by day 36 in phase 1. A combination with MET-097i is in early trials. If that pairing works, the monthly regimen could move into the efficacy tier where cross-trial caveats stop mattering.

Regulatory timeline. Ten phase 3 trials are advancing in 2026, including VESPER-4 (weekly), VESPER-5 (weekly, type 2 diabetes), and VESPER-6 (monthly). Approval before 2028 is unlikely.

Key Takeaways

MET-097i (PF'3944) is an ultra-long-acting GLP-1 receptor agonist with a ~16-day half-life, designed for once-monthly subcutaneous dosing after a weekly titration period.
Phase 2b produced 14.1% placebo-adjusted weight loss on weekly dosing (VESPER-1, 28 weeks) and 12.3% on monthly maintenance (VESPER-3, 28 weeks) — 10.5% under the more conservative estimand.
Tolerability is the differentiator: 2.9% total discontinuation in VESPER-1, and no severe diarrhea in VESPER-3.
Weight loss continued after the switch from weekly to monthly, with no plateau at week 28.
All figures are sponsor-reported topline data. Efficacy is not directly comparable to 52–72 week trials of approved drugs.
The drug is not available. Phase 3 began in 2026; approval is years away.

For anyone currently on a weekly GLP-1 and struggling with adherence or gastrointestinal side effects, the practical move is optimizing the current regimen — dose timing, titration pace, and nausea management — with a prescribing clinician, not waiting for a drug that has not finished phase 3.

References

Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. 2025;8(1):e2457349. DOI: 10.1001/jamanetworkopen.2024.57349
Rodriguez R, Hergarden A, Krishnan S, et al. Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy. Cell Reports Medicine. 2025;6(6):102156. DOI: 10.1016/j.xcrm.2025.102156
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205–216. DOI: 10.1056/NEJMoa2206038
Jastreboff AM, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. New England Journal of Medicine. 2025;393:843–857. DOI: 10.1056/NEJMoa2504214
McEwan P, Baker-Knight J, Ásbjörnsdóttir B, et al. Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China. European Journal of Health Economics. 2022;24(2):187–196. DOI: 10.1007/s10198-022-01470-w

Note: Efficacy, safety, and pharmacokinetic figures for MET-097i / PF'3944 are drawn from Metsera and Pfizer topline announcements and conference presentations. They have not been published in a peer-reviewed journal and should be treated as preliminary.

Last updated: 2026-07-30 Medical review: Dr. James Chen, MD, PhD, FACE